Mylan (MYL) PT Lowered to $48.00 at Citigroup
Several other research analysts have also weighed in on MYL. Leerink Swann dropped their price objective on shares of Mylan from $53.00 to $47.00 and set an outperform rating on the stock in a research note on Thursday. BidaskClub lowered shares of Mylan from a buy rating to a hold rating in a research note on Friday, June 22nd. Raymond James lowered shares of Mylan from a strong-buy rating to an outperform rating in a research note on Thursday. ValuEngine upgraded shares of Mylan from a sell rating to a hold rating in a research note on Wednesday, June 13th. Finally, Cantor Fitzgerald set a $41.00 price target on shares of Mylan and gave the stock a hold rating in a research note on Friday, June 29th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Mylan currently has an average rating of Buy and a consensus price target of $46.07.
Mylan stock traded up $0.60 during trading hours on Thursday, hitting $37.21. The company had a trading volume of 5,601,928 shares, compared to its average volume of 5,095,309. The firm has a market cap of $18.87 billion, a PE ratio of 8.16, a P/E/G ratio of 1.17 and a beta of 1.34. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.65 and a current ratio of 1.29. Mylan has a fifty-two week low of $29.39 and a fifty-two week high of $47.82.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Menora Mivtachim Holdings LTD. boosted its holdings in shares of Mylan by 219.1% during the 1st quarter. Menora Mivtachim Holdings LTD. now owns 7,057,501 shares of the company’s stock worth $290,557,000 after buying an additional 4,845,703 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Mylan by 32.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 9,408,218 shares of the company’s stock worth $340,012,000 after buying an additional 2,284,545 shares during the period. OppenheimerFunds Inc. boosted its holdings in shares of Mylan by 221.4% during the 1st quarter. OppenheimerFunds Inc. now owns 1,607,915 shares of the company’s stock worth $66,198,000 after buying an additional 1,107,667 shares during the period. Kornitzer Capital Management Inc. KS bought a new stake in shares of Mylan during the 2nd quarter worth $38,614,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Mylan by 522.2% during the 2nd quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,131,937 shares of the company’s stock worth $40,908,000 after buying an additional 950,000 shares during the period. Institutional investors own 83.39% of the company’s stock.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Further Reading: NASDAQ
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.